8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the 

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2015

Shire plc 

_________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands 

_________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630	98-0601486
(Commission File Number)	(IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin 

24, Republic of Ireland

_________________________________________________________________________

(Address of principal executive offices)	(Zip code)
Registrant’s telephone number, including area code	+353 1 429 7700

_________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01.   Other Events

Shire plc have issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

Item 9.01.   Financial Statements and Exhibits

(d) Exhibits. The following exhibit is filed herewith:

99.1 Press Release dated October 28, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ B Mordan
Name:   Bill Mordan
Title:     Company Secretary

Dated: October 28, 2015

EXHIBIT INDEX
Number	Description
99.1	Press Release dated  October 28, 2015

EX-99.1

EXHIBIT 99.1

Press Release  www.shire.com   

Director/PDMR Share Dealings

October 28, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that deferred American Depositary Shares (“ADSs”) granted to Phil Vickers, a Person Discharging Managerial Responsibilities, were automatically released today in accordance with the terms of a deferred share award granted on November 11, 2013. One ADS is equal to three Ordinary shares of 5 pence each in the Company.

The number of ADSs released and the number that lapsed are as follows:

ADSs Released(1)	ADSs Lapsed(2)
493	442

(1) In accordance with the terms of the deferred share award, the vested deferred ADSs were increased by an amount equivalent, at the date of vesting, to the value of dividends paid by the Company in respect of the deferred ADSs from the date of grant to the date of vesting.

(2) The number of ADSs lapsed is equivalent in value to Mr. Vickers’ tax liability resulting from the release of the deferred ADSs.

No amount was payable by Mr. Vickers in respect of the release of the deferred ADSs.

This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations
Matthew Osborne	mattosborne@shire.com	+1 781 482 9502
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX